<DOC>
	<DOCNO>NCT00598312</DOCNO>
	<brief_summary>The purpose study demonstrate safety efficacy Leuprolide Acetate Injectable Suspension 22.5 mg reduce serum testosterone castrate level patient prostate cancer .</brief_summary>
	<brief_title>Safety Efficacy Study Leuprolide Acetate Injectable Suspension 22.5 MG Treatment Prostate Cancer</brief_title>
	<detailed_description>This study open-label , multi-center study minimum 165 patient receive one ( 1 ) three ( 3 ) lot Oakwood Laboratories ' Leuprolide Acetate Injectable Suspension 22.5 mg two cycle . A subset patient ( minimum 12 ) assign lot ( A , B C ) additional blood sample characterize leuprolide release kinetics dose administer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Reads , understand able willing sign inform consent form Males great equal age 45 Histologically cytologically document prostate carcinoma Candidate initial hormone therapy inclusive patient begin neoadjuvant intermittent therapy , treat locally advanced disease , patient begin therapy failure prior local therapy Patients prior LHRH therapy adjuvant neoadjuvant setting , provide last date effective therapy great 6 month prior screen ECOG 02 Morning serum testosterone level &gt; 150 ng/dL Standard screening lab within 2x ULN ( AST , ALT , bilirubin serum creatinine ) Hemoglobin &gt; 10 g/dL Life expectancy &gt; 1yr . Willing complete cycle procedure study Any prior ( except prior LHRH therapy adjuvant neoadjuvant setting ) current definitive therapy prostate cancer , include chemotherapy , immunotherapy , tumorvaccines , biological response modifier , estrogens Patients undergone prostatic surgery within 4 week Baseline Patients undergone orchiectomy , adrenalectomy , hypophysectomy Patients currently hospitalize require frequent hospitalization Prior resistance LHRH therapy , either neoadjuvant adjuvant . Patients evidence spinal cord compression , ureteral obstruction clinically significant bladder outlet obstruction Participation investigational drug , biologic , device study within five halflives physiological action three month prior enrollment , whichever long Patients anticipate need concomitant hormonal , antiandrogen , radio , chemo , immuno surgical therapy prostate cancer study History recent drug and/or alcohol abuse within 6 month screen History HIV , HCV HBV infection History hypersensitivity know allergy LHRH agonist antagonists Concurrent use daily corticosteroid agent know modify serum androgen within 12 week screen visit Patients antiandrogens flutamide , nilutamide bicalutamide History cancer exception nonmetastatic basal squamous cell carcinoma skin Patients receive type 5alpha reductase inhibitor Proscar , Propecia , Avodart within past 3 month Patients experience myocardial infarction , unstable uncontrolled cardiovascular disease coronary vascular procedure within 6 month Baseline Patients experience venous thrombosis within 6 month Baseline Patients serious intercurrent illness ( e ) disease ( ) might interfere , put additional risk , ability receive treatment outline protocol Patients history follow : Immunization within 4 week Baseline ; Flu shot within 2 week Baseline ; Donation receipt blood blood product within 2 month Baseline ; Anaphylaxis Patients receive Oakwood 's leuprolide acetate formulation previously .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>